Diabetes and metabolic syndrome (MS)

Archives of Gerontology and Geriatrics

Volumn 44, Issue SUPPL., 2007, Pages 61-67

  Bellomo, A ^a   Mancinella, M ^a   Troisi, G ^a   Ettorre, E ^a   Marigliano, V ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Diabetes in elderly; Endothelial dysfunction; Hypercholesterolemia; Metabolic syndrome (MS); Treatment with statins

Indexed keywords

ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN; GLIBENCLAMIDE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; OLMESARTAN; OMEGA 3 FATTY ACID; ORAL ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; ROSUVASTATIN; SIMVASTATIN; THYROID HORMONE; TRIACYLGLYCEROL;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLUSTER ANALYSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; INFLAMMATORY DISEASE; INSULIN RESISTANCE; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; OBESITY; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; METABOLIC SYNDROME X; PYRIMIDINES; SULFONAMIDES;

EID: 33847049851     PISSN: 01674943     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.archger.2007.01.009     Document Type: Article

References (18)

1. ADA (American Diabetes Association) (2001): Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care, 24 (Suppl.1), S5-S20.
2. Alberiche M., Bonadonna R.C., and Muggeo M. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes 74 (1998) 1643-1649
3. Albert M.A., Danielson E., Rifai N., Ridker P.M., and for the PRINCE investigators. Effect of statin therapy on C-reactive protein levels. The Pravastatin Inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. J. Am. Med. Assoc. 286 (2001) 64-67
4. ATP III (Adult Treatment Panel III) (2001): Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. J. Am. Med. Assoc, 285, 2486-2497.
5. Brewer H.B. Benefit-risk assessment of rosuvastatina 10 to 40 mg. Am. J. Cardiol. 92 (2003) 260-297
6. Brown M.S., and Goldstein J.L. A receptor-mediated pathway for cholesterol homeostasis. Science 232 (1986) 34-47
7. Eckel R.H., Krauss R.M., and for the AHA Nutrition Committee. American Heart Association call to action: obesity as a major risk factor for coronary heart disease. Circulation 97 (1998) 2099-2100
8. Einhorn D., Reaver G.M., Cobin R.H., Ford E., Ganda O.P., Handelsaman Y., Hellman R., Jellinger P.S., Kendall D., Krauss R.M., Neufeld N.D., Petak S.M., Rodbard H.W., Seibel J.A., Smith D.A., and Wilson P.W. American college of endocrinology position statement on the insulin resistance syndrome. Endocr. Pract. 9 (2003) 237-252
9. Ellen R.L., and McPherson R. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. Am. J. Cardiol. 81 (1998) 60B-65B
10. Ginsberg H.N. Insulin resistance and cardiovascular disease. J. Clin. Invest 106 (2000) 453-458
11. Grundy S.M. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am. J. Cardiol. 81 (1998) 18B-25B
12. Kronmal R.A., Cain K.C., Ye Z., and Omenn G.S. Total serum cholesterol levels and mortality risk as a function of age. Arch. Intern. Med. 153 (1993) 1065-1073
13. Miller G.J. Lipoprotein and thrombosis: effects of lipid lowering. Curr. Pin. Lipidol. 6 (1995) 38-42
14. Reaven G.M. Banting Lecture: Role of insulin resistance in human disease. Diabetes 37 (1988) 1595-1607
15. Tenenbaum A., Fisman E.Z., and Motro M. Metabolic syndrome and type 2 diabetes mellitus: focus on peroxisome proliferator activated receptors (PPAR). Cardio-vasc. Diabetol. 23 2 (2003) 4
16. UKPDS (UK Prospective Diabetes Study) (1998): Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet, 352, 837-853.
17. WHO (World Health Organization) (2003): Definition, diagnosis and classification of diabetes mellitus and its complication: report of a WHO Consultation. Part 1: diagnosis and classification of diabetes mellitus. Geneva, Switzerland: World Health Organization. Accessed December 12.
18. Zimmet P. Globalization, coca-colonization and the chronic disease epidemic: can the doomsday scenario be averted?. J. Intern. Med. 247 (2000) 301-310